1-[2-(2-Aminooxyethoxy)ethoxy]-3-methylbutan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[2-(2-Aminooxyethoxy)ethoxy]-3-methylbutan-2-one
• 英文别名: 1-[2-(2-aminooxyethoxy)ethoxy]-3-methylbutan-2-one
• 化学式: C₉H₁₉NO₄
• 分子量: 205.25
• InChiKey: DCQWGORGWLXGDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  14
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING
  申请人：Genzyme Corporation

  公开号：US20140294867A1

  公开（公告）日：2014-10-02

  The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.

  本公开提供了结合多肽（例如抗体）及其效应物基团共轭物（例如抗体药物共轭物或ADCs），其中包括结合多肽的天然或工程糖醛中的位点特异性设计的药物-糖醛连接。本公开还提供了编码抗原结合多肽的核酸、重组表达载体和宿主细胞，用于制备这种抗原结合多肽。还提供了使用本文所披露的抗原结合多肽治疗疾病的方法。
• US20140271676A1
  申请人：——

  公开号：US20140271676A1

  公开（公告）日：2014-09-18
• HYPERGLYCOSYLATED BINDING POLYPEPTIDES
  申请人：Genzyme Corporation

  公开号：US20150079070A1

  公开（公告）日：2015-03-19

  Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
• Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1
  申请人：VICTORIA LINK LIMITED

  公开号：US20150291644A1

  公开（公告）日：2015-10-15

  The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, processes for preparing the compounds, and methods of treating diseases or conditions in which it is desirable to inhibit β-secretase.
• SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES
  申请人：Genzyme Corporation

  公开号：US20160060354A1

  公开（公告）日：2016-03-03

  The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.